Annual CFO
-$23.61 M
-$3.24 M-15.91%
31 December 2023
Summary:
Chemomab Therapeutics annual cash flow from operations is currently -$23.61 million, with the most recent change of -$3.24 million (-15.91%) on 31 December 2023. During the last 3 years, it has fallen by -$18.37 million (-350.42%). CMMB annual CFO is now -350.42% below its all-time high of -$5.24 million, reached on 31 December 2020.CMMB Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
N/A
01 September 2024
Summary:
Chemomab Therapeutics quarterly cash flow from operations is not available.CMMB Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
N/A
01 September 2024
Summary:
Chemomab Therapeutics TTM cash flow from operations is not available.CMMB TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CMMB Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -15.9% | - | - |
| 3 y3 years | -350.4% | - | - |
| 5 y5 years | - | - | - |
CMMB Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -350.4% | at low | ||||
| 5 y | 5 years | -350.4% | at low | ||||
| alltime | all time | -350.4% | at low |
Chemomab Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$23.61 M(+15.9%) | - | - |
| June 2023 | - | -$7.49 M(+4.2%) | -$25.63 M(+7.5%) |
| Mar 2023 | - | -$7.19 M(+26.0%) | -$23.84 M(+17.1%) |
| Dec 2022 | -$20.37 M(+64.6%) | -$5.70 M(+8.5%) | -$20.37 M(+16.0%) |
| Sept 2022 | - | -$5.25 M(-7.8%) | -$17.56 M(+18.0%) |
| June 2022 | - | -$5.70 M(+53.6%) | -$14.89 M(+0.6%) |
| Mar 2022 | - | -$3.71 M(+28.2%) | -$14.79 M(+19.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$12.37 M(+136.1%) | -$2.89 M(+12.2%) | -$12.37 M(+12.1%) |
| Sept 2021 | - | -$2.58 M(-54.0%) | -$11.04 M(+17.9%) |
| June 2021 | - | -$5.61 M(+333.6%) | -$9.36 M(+102.4%) |
| Mar 2021 | - | -$1.29 M(-16.8%) | -$4.62 M(-11.8%) |
| Dec 2020 | -$5.24 M | -$1.55 M(+72.6%) | -$5.24 M(+42.2%) |
| Sept 2020 | - | -$901.00 K(+3.2%) | -$3.69 M(+32.3%) |
| June 2020 | - | -$873.00 K(-54.4%) | -$2.79 M(+45.6%) |
| Mar 2020 | - | -$1.91 M | -$1.91 M |
FAQ
- What is Chemomab Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Chemomab Therapeutics?
- What is Chemomab Therapeutics annual CFO year-on-year change?
- What is the all time high quarterly CFO for Chemomab Therapeutics?
- What is the all time high TTM CFO for Chemomab Therapeutics?
What is Chemomab Therapeutics annual cash flow from operations?
The current annual CFO of CMMB is -$23.61 M
What is the all time high annual CFO for Chemomab Therapeutics?
Chemomab Therapeutics all-time high annual cash flow from operations is -$5.24 M
What is Chemomab Therapeutics annual CFO year-on-year change?
Over the past year, CMMB annual cash flow from operations has changed by -$3.24 M (-15.91%)
What is the all time high quarterly CFO for Chemomab Therapeutics?
Chemomab Therapeutics all-time high quarterly cash flow from operations is -$873.00 K
What is the all time high TTM CFO for Chemomab Therapeutics?
Chemomab Therapeutics all-time high TTM cash flow from operations is -$1.91 M